Oscar Health: Scale Is Finally Showing Up On The Bottom-Line

Oscar Health has surged over 100% since April, outperforming the benchmark, with a forward P/S of 0.50 suggesting undervaluation. The company's continued revenue growth and margin expansion support a Buy rating. Elevated short interest reflects market skepticism, but structural concerns appear limited.